慢病毒造血干/祖细胞基因治疗Wiskott-Aldrich综合征的长期安全性和有效性
该研究对8例接受慢病毒载体基因治疗的Wiskott-Aldrich综合征(WAS)患者进行中位7.6年的长期随访(I/II期试验NCT02333760),重点评估血小板减少和自身免疫。基因校正细胞稳定植入,未发生严重治疗相关不良事件,严重感染和湿疹消退,自身免疫病和出血事件显著减少,尽管血小板部分仅部分校正。结果表明慢病毒基因治疗为WAS患者提供持续临床获益。
要点
- 8例WAS患者接受慢病毒基因治疗后中位随访7.6年,基因校正细胞稳定植入。
- 未发生严重治疗相关不良事件,严重感染和湿疹消退。
- 自身免疫病和出血事件显著减少,尽管血小板部分仅部分校正。
核心结论
- 慢病毒基因治疗为WAS患者提供持续临床获益。
研究设计与样本
- I/II期慢病毒载体基因治疗试验(NCT01347346和NCT01347242)的长期随访研究(NCT02333760),纳入8例WAS患者,中位随访7.6年。
主要发现
- 基因校正细胞稳定植入,未发生严重治疗相关不良事件。
- 严重感染和湿疹消退。
- 自身免疫病和出血事件显著减少,尽管血小板部分仅部分校正。
关键数值与推荐
- 主要结局为评估基因治疗后3年至15年严重不良事件的发生率和类型以及临床状态和生物学参数(包括不同细胞亚群中慢病毒基因组整合位点)以确定临床和生物学安全性、有效性和耐受性。
- 次要结局包括监测额外治疗需求和T细胞受体库多样性。
- 中期分析显示研究满足所测试的主要结局标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with Wiskott-Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long-term follow-up results (median follow-up, 7.6 years) (phase I/II trial no. NCT02333760 ) for eight patients with WAS having undergone phase I/II lentiviral vector-based gene therapy trials (nos. NCT01347346 and NCT01347242 ), with a focus on thrombocytopenia and autoimmunity. Primary outcomes of the long-term study were to establish clinical and biological safety, efficacy and tolerability by evaluating the incidence and type of serious adverse events and clinical status and biological parameters including lentiviral genomic integration sites in different cell subpopulations from 3 years to 15 years after gene therapy. Secondary outcomes included monitoring the need for additional treatment and T cell repertoire diversity. An interim analysis shows that the study meets the primary outcome criteria tested given that the gene-corrected cells engrafted stably, and no serious treatment-associated adverse events occurred. Overall, severe infections and eczema resolved. Autoimmune disorders and bleeding episodes were significantly less frequent, despite only partial correction of the platelet compartment. The results suggest that lentiviral gene therapy provides sustained clinical benefits for patients with WAS.
引用
- Magnani A, Semeraro M, Adam F, et al. Long-term safety and efficacy of lentiviral hematopoietic stem/progenitor cell gene therapy for Wiskott-Aldrich syndrome. Nat Med. 2022. PMID: 35075289. doi:10.1038/s41591-021-01641-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。